Medsaic Pty Ltd was formed to commercialise a platform technology based on a protein microarray for the diagnosis of disease through the identification of patterns of antigen expression on cells.
Medsaic's first commercial-ready DotScan™ product is for the diagnosis of leukaemia and lymphoma. |
The system consists of a microscope slide dotted with an array of specific antibodies which capture cells, a proprietary slide scanner to record the pattern of cell binding, and software to interpret the binding pattern which leads to a diagnosis.
Medsaic occupies premises at the Australian Technology Park in Sydney, Australia, which include laboratories, offices and clean rooms for kit assembly. |
